Osivax Commences Human Trials for Sarbecovirus Vaccine Candidate OVX033

Osivax, a biopharmaceutical firm, has initiated a Phase 1 clinical trial for its sarbecovirus vaccine candidate, OVX033, in France. The study, which will include 48 participants, aims to assess the vaccine's safety and ability to provoke an immune response at varying dosages. The vaccine has shown cross-protection against three SARS-CoV-2 variants in preclinical studies and has demonstrated a strong safety profile in animal toxicology tests. The clinical trial is being conducted under the direction of Professor Odile Launay at the Clinical Investigation Center in Vaccinology Cochin Pasteur in Paris.
OVX033 is designed to target the nucleocapsid (N) protein of the coronavirus, which is less prone to mutation compared to surface proteins, potentially offering broader protection against different strains and future variants. The vaccine candidate is based on Osivax's proprietary OligoDOMTM technology, which has shown promise in the development of a broad-spectrum influenza vaccine, OVX836, currently in Phase 2 trials.
The Phase 1 study is a randomized, double-blind, placebo-controlled design, administering a single dose of the vaccine or a placebo to healthy individuals aged 18-49. The trial's findings will contribute to the advancement of a vaccine that could protect against all SARS-CoV-2 variants and future coronavirus threats. The project is backed by the French government through the "Programme Investissements d’Avenir."

Osivax is focused on creating innovative vaccines that elicit robust T-cell and B-cell responses against a range of respiratory viruses. The company's goal is to develop a vaccine that can prevent all strains of influenza and Covid-19 variants in a single dose, and it is exploring opportunities to expand its technology to other infectious diseases through partnerships and collaborations globally.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!